The American Association for the Study of Liver Diseases, Infectious Diseases Society of America, and International Antiviral Society-USA Hepatitis C Guidance Update (July 2016)
Summary: This version of guidance for those prescribing hepatitis C treatments was updated to included recent developments, such as the approval of the hepatitis C treatment Epclusa (sofosbuvir/velpatasvir).
Summary: The study evaluated Zepatier (elbasvir/grazoprevir) in treating hep C in those who inject drugs (PWID) while being treated for opioid use with opioid-agonist therapy (OAT). The study resulted in high rates of SVR12/’cure rates’ and low levels of side effects, regardless of ongoing drug use. (hivandhepatitis.com blog post with more information)
- A Needs Assessment of the Number of Comprehensive Addiction Care Physicians Required in a Canadian Setting by J. McEachern, et al.
Summary: Using population estimates, the assessment found 23 certifed physicians for every 1000 affected individuals. The study highlighted the need for more healthcare provider training for rural health regions. (CBC post with more information)
Summary: This head-2-head study compared the safety and efficacy of Zepatier (elbasvir/grazoprevir) and Sovaldi (sofosbuvir) plus pegylated interferon/ribavirin (PR) in patients with hep C who were mainly treatment-naive, without liver cirrhosis, and had hep C genotype 1b. The study found that the SVR12/cure rates were 99.2% (Zepatier) and 90.5% (Sovaldi/PR). Both treatments only caused very low rates of side effects.
Global genotype distribution of hepatitis C viral infection among people who inject drugs by Geert Robaeys, et al.
Summary: There is a different occurrence of hep C virus types in persons who inject drugs than in the general population. Especially with hep C genotype 3 that is more common in persons who inject drugs than it is in the general population in Western countries.
Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution by Jean-Charles Nault, et al.
Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial by Zobair M Younossi, et al.
Summary: This is an assessment of patient outcomes looking only at patient-reported outcomes (PROs) by patients with liver cirrhosis who took Epclusa (sofosbuvir and velpatasvir) with and without ribavirin. The study found that PROs, such as emotional, mental, and social well-being as well as work productivity, dipped during the hep C treatment but improved after it.
- Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study by George Lau, et al.
Summary: In this proof-of-concept study, patients were give hep C treatments (sofosbuvir, ledipasvir, and asunaprevir; sofosbuvir, daclatasvir, and simeprevir; and sofosbuvir, daclatasvir, and asunaprevir) for only 3 weeks instead of the usual 12 or 24 weeks. The treatments were successful.
Recent Press Releases by Pharmaceutical Companies
- How a World Free from Viral Hepatitis is Possible: An Interview with Raquel Peck, CEO of the World Hepatitis Alliance
- AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
- CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)
- European Commission Grants Marketing Authorization for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C